248P Real-world relapse-free survival in HR+/HER2- breast cancer with PAM50 intermediate-risk group
Santiago Terán(Hospital Universitario 12 De Octubre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Mireia Moreno, María Luz Fernández(Columbia University), L. Lema Roso(Hospital Universitario 12 De Octubre), A. Madariaga Urrutia(Hospital Universitario 12 De Octubre), E.M. Ciruelos(Hospital Universitario 12 De Octubre), C. Gonzalez Deza(Hospital Universitario 12 De Octubre), L.M. Manso Sànchez(Hospital Universitario 12 De Octubre), M. Quevedo(Hospital Universitario 12 De Octubre), Manuel Alva Bianchi(Research Institute Hospital 12 de Octubre), L. Parrilla Rubio(Hospital Universitario 12 De Octubre), P. Tolosa Ortega(Hospital Universitario 12 De Octubre), Yolanda Ruano(Hospital Virgen de la Salud)
Cited by 0
Related Papers
Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and <i>BRAF</i> <i>V600E</i> mutation
|The Journal of Experimental Medicine|2019|136
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
|British Journal of Cancer|2017|106
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer
|JAMA Oncology|2024|77
Identification of survival‐related genes of the phosphatidylinositol 3′‐kinase signaling pathway in glioblastoma multiforme
|Cancer|2008|70
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
|Nature Communications|2023|65